CAMBRIDGE, Mass., and TOKYO, Mar 22, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually.

Four key symposium presentations explored how lecanemab's clinical efficacy data, overall amyloid-related imaging abnormality (ARIA) rates, biomarker relationships to clinical outcomes, potential dosing regimens, and administration have the potential to benefit people living with early AD.

1. Science of the Amyloid Cascade and Distinct Mechanism of Action (MoA) of Lecanemab

- BioArctic's Professor Lars Lannfelt presented the science of the amyloid cascade and studies evaluating lecanemab's distinct binding profile to antibodies created from patented sequences of two other clinical antibodies, aducanumab and gantenerumab. The three antibodies have different binding profiles to Abeta species. All three antibodies bind to fibrils, but with different selectivity. Lecanemab was the strongest Abeta binder and prefers protofibrils. Lecanemab's binding profile is critical to enriching our understanding of the features in clinical outcomes and safety. BioArctic has had a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of AD.

2. Key Trial Design Aspects and Clinical Outcomes of the Lecanemab Phase 2b (Study 201) Trial and Open-Label Extension (OLE) in Early AD

- Innovative Bayesian Adaptive Randomization Design and Dose Regimen-Finding Study with OLE - Study 201 (published by Eisai in Alz Res Therapy 13;21) was prospectively designed as a blinded 18-month study. To accelerate the development program, Eisai used a Bayesian adaptive design with a prespecified 12-month Bayesian primary endpoint in addition to the prespecified traditional analysis at the end of the 18-month treatment period. The OLE evaluated the long-term safety and tolerability of lecanemab and the effect of lecanemab on amyloid PET over 12 months of treatment, which looked at treatment naive patients (those on placebo during the core study) and those patients who had previously been treated with lecanemab, including earlier time points (3 and 6 months) than in the core phase (12 and 18 months). Eisai's study design provided the opportunity to explore the biomarker and clinical effects of stopping and restarting lecanemab across five years of disease trajectory.

- Rapid and Thorough Amyloid Clearance Correlates with Clinical Benefit - By using the Bayesian study design across a broad range of doses, researchers were able to efficiently and effectively identify the most effective dose, 10 mg/kg biweekly, to produce rapid and thorough amyloid clearance and potential clinical efficacy. Of the approximately 12 treatment-naive patients in the OLE (those who received placebo in the Core study), more than 40 percent were amyloid negative as early as 3 months and more than 80% were amyloid negative by 12 months as measured by PET image (visual read).(1) The OLE results are consistent with core phase results in which 65% were amyloid negative at 12 months(1) and 81% of participants were amyloid negative at 18 months as measured by PET image (visual read) in 161 subjects treated with 10 mg/kg biweekly dose. Robust amyloid reduction in those receiving lecanemab in the Core study was maintained while off-treatment over the Gap period. Despite the small number of participants in the OLE, findings help confirm the results from the Core study: lecanemab rapidly and thoroughly cleared amyloid plaque from the brain. Study 201 established 10 mg/kg biweekly as the most effective dose of lecanemab based on ADCOMS. Lecanemab could potentially be administered at 10mg/kg on the first day of treatment and continue at biweekly intervals without titration.

ARIA Incidence, Frequency, Severity and Modeling
ARIA-E is an important adverse event of amyloid-lowering therapies that is critical to monitor and manage during treatment.

Study 201 Core ARIA-E Rates
ARIA-E was observed in allele groups administered 10 mg/kg biweekly at the following rates: overall ApoE4 carriers 14.3% (7/49), ApoE4 carriers homozygous 50.0% (5/10), ApoE4 carriers heterozygous 5.1% (2/39) and ApoE4 non-carriers 8.0% (9/112). The overall ARIA-E rate in the Core study was 9.9% (16/161) of patients treated with lecanemab 10 mg/kg biweekly compared with 0.8% (2/245) of placebo patients.

Study 201 OLE ARIA-E Rates
Although ApoE carriers were underrepresented in the 10 mg/kg biweekly group in Study 201 Core, all participants entering Study 201 OLE (69.4% of whom were ApoE4 carriers) were treated with 10 mg/kg biweekly, and ARIA rates were consistent with those in the Core study. Forty-five participants who received placebo in the Core study joined the OLE. ARIA-E was observed in allele groups newly treated with 10 mg/kg biweekly in the OLE at the following rates: overall ApoE4 carriers 12.9% (4/31), ApE4 carriers homozygous 25.0% (1/4), ApoE4 carriers heterozygous 11.1% (3/27) and ApoE4 negative 0.0% (0/14). In the OLE study, overall ARIA-E rates were as follows: ApoE4 carriers 10.4% (13/125), ApoE4 carriers homozygous 14.3% (4/28), ApoE4 carriers heterozygous 9.3% (9/97) and ApoE4 non-carriers 1.8% (1/55).

Study 201 Core and OLE Pooled ARIA-E Rates
In the Core and the OLE, ARIA-E was observed in allele groups administered 10 mg/kg biweekly at the following rates: ApoE4 carriers 13.8% (11/80), ApoE4 carriers homozygous 42.9% (6/14), ApoE4 carriers heterozygous 7.6% (5/66) and ApoE non-carriers 7.1% (9/126). The overall ARIA- E rate was 9.7% (20/206) of patients treated with lecanemab 10 mg/kg biweekly.

ARIA-E Rates Frequency and Severity
In the Core study and OLE, the majority of ARIA-E events occurred within the first 3 months of treatment (75% [12/16]) and resolved within 4 months of onset. For the majority of patients, the radiographic severity was mild or moderate; severe radiographic severity was reported in 1.2% (2/161) of patients. The majority of ARIA-E was asymptomatic; with symptomatic ARIA-E reported in 1.9% (3/161) of patients. Symptoms reported in association with ARIA-E included headache, visual disturbance, confusion, aphasia. There has been a single case of ARIA-E associated with seizure in the Core study and OLE to date.

Exposure-Response Model Predicted and Observed ARIA-E vs. Cmax for APOE 4
The PK/PD exposure-ARIA-E model was developed from the Core study utilizing data from all doses and demonstrated that ARIA-E is driven primarily by Cmax. The ApoE4 genotype is a significant covariate in the model. The PK/PD model predicted ARIA-E by Cmax at the 10 mg/kg biweekly dose in the Core study by allele group as follows: ApoE4 carriers homozygous 22.5%, ApoE4 carriers heterozygous 6.8% and ApoE4 non-carriers 5.4%. In addition to the modeling predicting ARIA-E by Cmax in the Core study, it confirmed the observed ARIA-E in the OLE. Given the small data set for ApoE4 homozygous patients, this will be evaluated in Eisai's Phase 3 Clarity AD clinical trial.

ARIA-H Rates
In the Core study, the incidence was higher in ApoE4 homozygous carriers than in ApoE4 heterozygous carriers and non-carriers. ARIA-H was observed in 6.2% (10/161) of patients treated with lecanemab 10 mg/kg biweekly compared with 4.9% (12/245) of placebo patients. The rate of ARIA-H was higher in ApoE4 carriers (12.2% [6/49] vs placebo 5.2% [9/174]), than in ApoE 4 non- carriers (3.6% [4/112] vs placebo 4.2% [3/71]). All patients with microhemorrhage or superficial siderosis were asymptomatic. There has been one report of symptomatic cerebral macrohemorrhage. These data are hypothesis-generating and will be further evaluated in Clarity AD.

3. Phase 2b (Study 201) Lecanemab Early AD Study Biomarker Results, Correlations with Clinical Outcomes and Potential Less-Frequent Maintenance Dosing

- Abeta42/40 and P-Tau181 are plasma biomarkers that signal sequential changes in AD progression. Lecanemab has an effect on these plasma biomarkers as amyloid plaque reduction is related to soluble amyloid and P-Tau. Lecanemab has a dose- and time-dependent reduction of amyloid plaques with a correlated increase in plasma Abeta42/40 and a decrease in plasma P-Tau181. Changes in plasma Abeta42/40 and P-Tau18 also correlate with change from baseline Clinical Dementia Rating scale Sum of Boxes (CDR-SB). In the Core study, a correlation in change from baseline in amyloid PET SUVR and plasma Abeta42/40 ratio and plasma P-tau181 was observed at 18 months, indicating that plasma biomarkers could potentially help with measuring clinical changes.

- When lecanemab treatment was discontinued at the end of the Core study, changes in the plasma Abeta42/40 (47%), P-Tau18 (24%), and amyloid PET SUVR (21%), gradually began to reverse, suggesting stopping therapy prematurely may potentially allow re-accumulation of pathology. Less frequent maintenance treatment to prevent re-accumulation may be possible based on data and modeling. Eisai will further explore maintenance dosing in the subcutaneous substudy of the Study 201 OLE, which will evaluate alternative dosing every 4 weeks or every 12 weeks.

- Increasing strong evidence highlights the role of amyloid plaques in triggering tau dysregulation and researchers optimize tau therapeutics by removing a key driver of tau dyshomeostasis (amyloid). For this reason, the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, selected lecanemab as the backbone anti-amyloid therapy for anti-tau combination for the ongoing component of the Tau NexGen clinical study, which continues enrollment efforts.

4. Update on Lecanemab Clinical Development, Including New Subcutaneous Formulation
Eisai's Dr. Michael Irizarry Senior VP of Clinical Research and Deputy Chief Clinical Officer presented updates on key lecanemab clinical trials.

- Clarity AD Phase 3: The innovative Bayesian design of lecanemab's robust dose-ranging Phase 2b study allowed Eisai to design the Phase 3 confirmatory Clarity AD clinical trial to verify lecanemab's clinical efficacy and safety in early AD. Enrollment is complete with 1,795 participants globally. Additionally, Eisai's recruitment strategy for the Clarity AD clinical trial ensured greater inclusion of ethnic and racial populations in the U.S., resulting in approximately 25% of the total U.S. enrollment including Hispanic (22.5%) and African American (4.5%) persons living with early AD, which mirrors the U.S. Medicare population. The readout will occur in Fall 2022.

- AHEAD3-45 Phase 3 Study in Preclinical AD: As of March 2022, there were over 2,900 people screened, resulting in 287 participants enrolled.

- Clarity AD Subcutaneous Substudy: Eisai is developing a subcutaneous formulation of lecanemab with the potential to be administered at home by the patient or caregiver via an auto-injector with a more rapid administration than the IV formulation (<15 second SC injection versus ~1h infusion). PK/PD modeling of Study 201 suggests that the average lecanemab concentration (Cave) predicts amyloid clearance while the maximal lecanemab concentration (Cmax) predicts ARIA-E rate. Since subcutaneous administration results in a blunted Cmax, the SC dose with comparable Cave to 10 mg/kg IV is hypothesized to have similar amyloid reduction with potentially reduced incidence of ARIA-E relative to IV but less than half the ARIA- E rate as IV. Eisai is evaluating the SC formulation in the Clarity AD OLE.

"The invited lecanemab presentations at AD/PD provide new and exciting insights into how the mechanism of action of late-stage anti-amyloid antibodies differ and how that may help simplify the patient journey by offering a less frequent dosing regimen while providing long-term benefit," said Lynn Kramer, M.D., Chief Clinical Officer, Neurology Business Group, Eisai. "Eisai aims to bring these potential innovations to people living with early AD and healthcare providers as quickly as possible as we work to fulfill our human health care mission."

Lecanemab was granted Breakthrough Therapy and Fast Track designations by the U.S. Food and Drug Administration (FDA) in June and December 2021, respectively. Eisai anticipates completing lecanemab's rolling submission of a Biologics License Application for the treatment of early AD to the FDA under the accelerated approval pathway. Eisai expects to complete this rolling submission in the first quarter of our fiscal year 2022, which begins April 1, 2022. Eisai initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data of lecanemab under the prior assessment consultation system in Japan in March 2022. Additionally, the readout of the Phase 3 confirmatory Clarity AD clinical trial will occur in the Fall of 2022. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully complete clinical development or gain health authority approval.

(1) Swanson C.et all, November, 9-12, 2021, Clinical Trials On Alzheimer's Disease Annual Meeting, Lecanemab: An Assessment of the Clinical Effects, the Correlation of Plasma Abeta 42/40 Ratio With Changes in Brain Amyloid PET SUVr, and Safety from the Core and Open Label Extension of the Phase 2 Proof-of- Concept Study, BAN2401-G000-201, in Subjects With Early Alzheimer's Disease.

Contacts:

MEDIA CONTACT:
Eisai Co., Ltd.
Public Relations Department
+81-(0)3-3817-5120

Eisai Inc. (U.S.) Libby Holman
+ 1-201-753-1945
[email protected]

INVESTOR CONTACT:
Eisai Co., Ltd.
Investor Relations Department
+81-(0)70-8688-9685

MEDIA CONTACT:
Biogen Inc. Ashleigh Koss
+ 1-908-205-2572
[email protected]

INVESTOR CONTACT:
Biogen Inc. Mike Hencke
+ 1-781-464-2442
[email protected]

For more information, visit https://www.eisai.com/news/2022/pdf/enews202221pdf.pdf.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually.

ZURICH, SWITZERLAND, Mar 22, 2022 - (JCN Newswire) - Hitachi Energy, the global technology and market leader in power grids, announced today that it has won an order from Suzano, the world's leading eucalyptus pulp producer and one of Latin America's largest paper producers, to design and deliver a complete grid connection solution for the company's new pulp mill in Brazil.

Suzano's new factory will be the world's largest single-line eucalyptus pulp mill and Brazil's first pulp production facility to be fossil fuel free when completed in the second half of 2024. It will have an annual production capacity of 2.5 million tons and will increase Suzano's output by 20 percent. About half of the electricity generated will be transferred to the national power grid, enough to supply around 2.3 million people for one month.

The two companies have worked closely together on grid solutions for Suzano's fleet of mills over the past 20 years. In this spirit of collaboration and co-creation, Hitachi Energy has contributed its pioneering technologies and its unique system integration capabilities, engineering expertise and extensive experience of local grid code requirements. This enables Hitachi Energy to design and supply complete solutions with exceptional levels of reliability, that are fundamental for these types of application.

"We are honored and delighted to be working with Suzano again on this landmark project that sets a new benchmark in sustainable pulp production and shares its emission-free electricity with society at large," says Niklas Persson, Managing Director of Hitachi Energy's Grid Integration business. "This is another example of how our solutions are advancing the world's energy system to be more sustainable, flexible and secure."

"The construction of the new factory is the biggest investment in Suzano's history, so it is vital that the grid connection through which we generate additional revenue from our surplus energy operates at outstanding levels of reliability and availability," says Mauricio Miranda, Engineering Director at Suzano. "We chose Hitachi Energy as our technology partner based on more than 20 years of successful collaboration and consistent delivery of innovative, reliable solutions and exceptional project execution."

Hitachi Energy will supply a state-of-the-art grid connection solution to enable the surplus renewable power to be transferred reliably, safely and securely into the national power grid. The solution's compact footprint is based on advanced gas-insulated switchgear and offers excellent performance in terms of efficiency and availability, while minimizing the total lifecycle cost and CO2 footprint.

To secure reliability and availability, key elements of the grid connection, such as the transformers will be equipped with Hitachi Energy's digital monitoring systems to provide real- time data and performance insights and enable predictive maintenance. Hitachi Energy will provide a complete solution across the value chain, from system studies and grid code compliance to design and engineering, supply and installation and commissioning.

Hitachi Energy is the world's leading provider of grid connections and power quality solutions, with an installed base of more than 10,000 projects worldwide, over 800 of which connect renewable energy sources to the grid.

About Hitachi Energy Ltd.

Hitachi Energy is a global technology leader that is advancing a sustainable energy future for all. We serve customers in the utility, industry and infrastructure sectors with innovative solutions and services across the value chain. Together with customers and partners, we pioneer technologies and enable the digital transformation required to accelerate the energy transition towards a carbon-neutral future. We are advancing the world's energy system to become more sustainable, flexible and secure whilst balancing social, environmental and economic value. Hitachi Energy has a proven track record and unparalleled installed base in more than 140 countries. Headquartered in Switzerland, we employ around 38,000 people in 90 countries and generate business volumes of approximately $10 billion USD.
https://www.hitachienergy.com
https://www.linkedin.com/company/hitachienergy
https://twitter.com/HitachiEnergy

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business. Hitachi is focused on strengthening its contribution to the Environment, the Resilience of business and social infrastructure as well as comprehensive programs to enhance Security & Safety. Hitachi resolves the issues faced by customers and society across six domains: IT, Energy, Mobility, Industry, Smart Life and Automotive Systems through its proprietary Lumada solutions. The company's consolidated revenues for fiscal year 2020 (ended March 31, 2021) totaled 8,729.1 billion yen ($78.6 billion), with 871 consolidated subsidiaries and approximately 350,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHitachi Energy, the global technology and market leader in power grids, announced today that it has won an order from Suzano, the world's leading eucalyptus pulp producer and one of Latin America's largest paper producers, to design and deliver a complete grid connection solution for the company's new pulp mill in Brazil.

The crypto platform seeks to offer DeFi projects liquidity incentives and achieve regulatory compliance for crypto firms

The post New $100M Fund Aims To Bolster Blockchain Development in Vietnam appeared first on Blockworks.

The post After Constant Rejection of Bitcoin(BTC) Price at $42,000, This May be the Expected Quarterly Close! appeared first on Coinpedia - Fintech & Cryptocurreny News Media| Crypto Guide

The star crypto Bitcoin is only displaying possibilities of flipping the bearish trend sometime in the near future. But woefully, ends up faking out with the breakout which usually ends up in a healthy accumulation. However, with the recent break-out above $41,800, the traders became a little confident but soon after hitting $42,200, they began …

Chains.com, an early-stage multiproduct cryptocurrency startup launched in February 2022,  has seen over 380,000 accounts created on the platform so far, in anticipation of the launch of the Chains Launchpad and Prism products.

“The traction so far underlines just how attractive Chains' offering proved to appear to a large cross-section of users,” says CEO and Founder of Chains.com, Anderson Mccutcheon. 

Anderson adds: “We saw a gap in the market for a platform supporting not only different cryptocurrencies and blockchains, but also services designed specifically for those not interested in the underlying technology”

Scaling from zero to hundreds of thousands of users meant that the company had to make significant adjustments, rapidly deploying changes to both the frontend and backend of its product.

The team introduced fingerprinting, multiple captcha touchpoints and account verification methods to eliminate risks posed by automated botting and DDoS attempts. 

Anderson says: “We can confidently say we are at a very low risk of being compromised thanks to the tireless work of our cyber security specialists. Our top priority is the security and stability of our systems. Users need to be able to trust us with their data.”

Over 30,000 users applied to have their accounts whitelisted for the upcoming CHA token sale on the Chains Launchpad and this is expected to rise as more details emerge about the presale.

Those who have signed up for the presale indicated TRON, Ethereum and Binance Smart Chain as the blockchains they prefer to have the token deployed on. The flexibility offered by Chains.com means users can pick and choose between a variety of chains to which their tokens are to be deployed after the token sale, an industry first.

About the Founders:

Anderson Mccutcheon, a former Riot Games and Stars Group executive, as well as an IDF Unit 8200 veteran, comes from a diverse technological and marketing background. A blockchain industry pioneer, Anderson co-founded Unicoin and Synereo and specializes in algorithm development for real-time thermochemical control systems. 

Assaf Patir, the Chains Chief Economist, holds two PhDs, one in Economics from Northwestern University and another in Physics from the Weitzmann Institute of Science. Assaf's specialty field is Macroeconomics and he currently holds the position of Chief Economist at the Start-Up Nation Policy Institute.

About Chains: Chains, a Seychelles International Business Company, was founded in 2020 with a view to simplify the cryptocurrency and NFT experience for non-technical users and create a gateway to access the space and relevant services on one platform.

Media Contact:

Daria Kuznetsova,
CMO of Chains.com
[email protected]

Russia’s invasion of Ukraine turned out to be a shock to the global community despite the threat that had been growing for months preceding it. Although the military action is taking place within the Ukrainian boundaries, the financial disruption it brought about has spread far beyond. The global stock market is tumbling, the oil and […]

The post The Future of Fintech In View of the War in Ukraine: Top Influencers’ Opinions appeared first on SDK.finance - White-Label Digital Core Banking Software.

As AI models get ever larger, the amount of money and energy required to train them has become a hot-button issue. A new approach that rewrites one of the fundamental building blocks of the discipline could provide a potential workaround. Ever since GPT-3 demonstrated the significant jumps in performance achievable by simply increasing model size, […]

The final week of the LCO Split 1 regular season is here. With all 5 places and both initial playoffs games already decided, this week will be one final chance to fine-tune before the best of fives begin. The playoffs will begin with Peace taking on Pentanet in the upper bracket first round, with the […]

The post A lower bracket preview is on the horizon as the LCO regular season hits the final straight — LCO Predictions Week 9: Day 1 appeared first on Snowball Esports.

TOKYO, Mar 21, 2022 - (JCN Newswire) - TOYOTA GAZOO Racing started the 2022 FIA World Endurance Championship (WEC) with a podium finish from an eventful and ultimately frustrating 1000 Miles of Sebring, which finished early due to a thunderstorm.
The GR010 HYBRID Hypercar's 100% winning record was brought to an end at the start of its second season of competition. Sebastien Buemi, Brendon Hartley and Ryo Hirakawa started the campaign with a podium for second place following a valiant battle in their #8 GR010 HYBRID in a race won by Alpine.

But World Champions Mike Conway, Kamui Kobayashi and Jose Maria Lopez did not see the chequered flag following an accident shortly before half distance. That put the #7 GR010 HYBRID out of the race, the first time that car has failed to finish since Le Mans 2017.

A difficult qualifying left the GR010 HYBRIDs in an unfamiliar grid position, with Sebastien starting fourth and Kamui seventh. That did not last long, however. Within four laps Sebastien moved up to third with Kamui just behind in fourth, joining an all-Hypercar battle for the podium positions.

When the two GR010 HYBRIDs made their first pit stops for a fuel top-up just before the hour mark, both overhauled the Glickenhaus. Second-placed Sebastien therefore led the chase of the leading Alpine, with Kamui following in the #7.

When the race entered its fourth hour, Jose had closed the gap on Brendon and, on lap 104, he overtook to move into second place. But facing a Balance of Performance deficit to the competition, neither GR010 HYBRID had a chance to challenge for the lead.

Midway through the fourth hour, the complexion of the race changed. Jose clashed with a lapped GT car and made contact with the tyre barrier. He attempted to bring the damaged car back to the pits but impacted heavily against the tyre barrier a few corners later, although thankfully he could leave the car unaided and unhurt.

The race was red flagged for 34 minutes as a result, which proved to be unfortunate timing for the #8 car. Brendon had to make an emergency fuel stop during the safety car restart before a full pit stop as soon as racing resumed a lap later. Ryo took over the #8 car to make his WEC race debut.

He completed an impressive double stint to extend the #8 car's advantage over the third-placed Glickenhaus before Sebastien took over the wheel for a final stint, which began with a full course yellow for debris on track.

With just over an hour remaining, the threat of lightening caused a red flag and, despite a brief attempt to restart behind the safety car, the race never resumed. The 2022 season continues in Europe, with the 6 Hours of Spa-Francorchamps on 7 May.

For more information, visit https://toyotagazooracing.com/wec/release/2022/rd01-race/.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comTOYOTA GAZOO Racing started the 2022 FIA World Endurance Championship (WEC) with a podium finish from an eventful and ultimately frustrating 1000 Miles of Sebring, which finished early due to a thunderstorm.

No matter how bad the price gets, Elon Musk – the famed South African billionaire behind companies such as Tesla and SpaceX – says he will not sell his digital currency. Elon Musk Loves His Bitcoins The price of bitcoin has experienced some rather rough fluctuations throughout the first few months of 2022. The currency...

The post Elon Musk: I’m Not Selling MY BTC appeared first on Live Bitcoin News.

CRO is the native token of the Cronos blockchain. It is used for staking activities on its cryptocurrency exchange Crypto.com. Before the launch of its blockchain, Cronos was an ERC-20 token launched on the Ethereum blockchain. Fees generated from transactions are used to reward the users who staked their CRO tokens at the end of the staking period. Stakers earn between 10% and 12% APY on their staked tokens. What is Cronos (CRO)? Cronos (CRO) was launched in the last quarter of 2018 as the cryptocurrency that will be used in Mobile payments on Crypto.com financial and cryptocurrency exchange. The Cronos chain is decentralized, open-sourced and allows the adoption of cryptocurrencies. Crypto.com exchanged was launched in June 2016 by Kris Marszalek, Rafael Melo, Gary Or, and Bobby Bao. The exchange is one of the foremost exchanges that permits buying of cryptocurrencies with fiat currencies. Cronos payment platform with Crypto.com rewards users with 20% cashback for paying fees with CRO and 10% for peer-to-peer tradings on the fees generated. Now, let’s see the price analysis of Cronos for the coming years. Price Analysis of Cronos (CRO) Flashback: Fundamental Analysis of Cronos (CRO) The Crypto.com token (CRO) was rebranded to Cronos (CRO) after the launch of its blockchain in 2021. This is important so that users can different activities within the Cronos blockchain from the activities with the Crypto.com exchange. This same rebranding was recently done by Binance exchange when it changed the name of Binance Coin (BNB) to Build and Build (BNB). Every good rebranding always gets good course for the token since the impacts will be seen soon on the price of Cronos (CRO). Also, there is an increase in the annual percentage yield (APY) on staking with CRO. The reward has been increased to up to 52% from the previous 10% to 12% APY. This will encourage long-term investors on the project to stake CRO, so as to receive more of it by the end of the duration. Now, let’s see charts on Cronos price analysis. https://www.tradingview.com/x/x4Z2Moiu/ From the chart above, the price of CRO is getting to a critical point, since the green curve called the lips on the William Alligator indicator is approaching the same level with the recent candlesticks formed. This can trigger a bullish reversal. https://www.tradingview.com/x/DH4Dhz5y/ The relative strength index of Cronos (CRO) is 42.04 from the chart above. This means that the present trend is neutral and a bearish or bullish movement is possible depending on who takes over the CRO market. https://www.tradingview.com/x/t9Hz1Dfq/ From the chart above that represents the Keltner Channel Indicator for the 1Day CRO/USDT-we can observe that the price of Cronos (CRO) is consolidating, though it is still within the first half of the channel from the bottom. Let’s see the price predictions of Cronos (CRO) for the next five years. Cronos (CRO) Price Prediction 2022 The present return on investment on CRO for the past one year is 100% at the time of writing. If this is repeated this year, the price of Cronos might reach $0.38, $0.48, $0.65, and $0.8 by the end of the first quarter, second quarter, third quarter, and fourth quarter respectively. Cronos (CRO) Price Prediction 2023 Cronos might reach $1.08, $1.48, $2.65 and $3 by the end of the first quarter, second quarter, third quarter, and fourth quarter of 2023 respectively. Cronos (CRO) Price Prediction 2024 Cronos might reach $3.2, $3.35, $3.5, and $4 by the end of the first quarter, second quarter, third quarter, and fourth quarter of 2024 respectively. Cronos (CRO) Price Prediction 2025 Cronos might reach $4.2, $5.35, $5.2, and $6 by the end of the first quarter, second quarter, third quarter, and fourth quarter of 2025 respectively. Cronos (CRO) Price Prediction 2026 Cronos might reach $6.4, 46.9, $7.5, and $8 by the end of the first quarter, second quarter, third quarter, and fourth quarter of 2026 respectively. Cronos (CRO) Price Prediction: Market Sentiments Cronos (CRO) price predictions according to well-known media platforms are explained below: Wallet Investors According to Wallet Investors, the price of CRO will be $1.02 by February 2023 and $3.44 by February 2027. PricePredictions According to PricePredictions, the price of CRO will be $0.56 in 2022, $0.82 in 2023, and $11 by 2030. Digital Coin Price According to Digital Coin Price, the price of CRO will be $0.57 in 2022 and $1.95 by 2030. Our Cronos (CRO) Price Prediction Due to the increase in the number of cryptocurrency users and the quick option that funding with fiat currencies offers, together with the high rewards on CRO APY for those who stake CRO, the price of Cronos (CRO) might reach $8 by 2026. Conclusion From the fundamental analysis, charts, and market sentiments around Cronos, we can deduce that the price of CRO will be bullish in the future which … Continued

The post Cronos Price Prediction 2022-2026-Will CRO Price Hit $0.8 by the end of 2022? appeared first on Cryptoknowmics-Crypto News and Media Platform.

'Framerate Insurance' fakes Quest 2 Air Link dropped frames to reduce judder on imperfect connections. Here's how to enable it: